ACC017 vs Bictegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

ACC017

Developed by Jiangsu Aidea Pharmaceutical Group

Phase 3 in HIVsmall molecule
Partial signal

NCT06719310 · Phase 1/2 · completed

The first stage of this study randomly assigned patients to ACC017 or placebo under double-blind conditions, a strong design, and its primary endpoints include the proportion of patients reaching an undetectable HIV-1 viral load, a disease-defining measure for HIV therapy. However, results have not yet been posted, so whether the drug met that goal is not yet known.

Next expected readout: June 2027 · NCT07711210 (registry estimate)

Reported efficacy

Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AE (Day 1- Day 11); HIV-1 RNA viral load change from baseline (Day 11); Proportion of patients with HIV-1 RNA viral load <50 copies/mL (Day 29); Pharmacokinetics parameter: Cτ,ss (Day 10, Day 29); Pharmacokinetics parameter: Cmin,ss (Day 10); Pharmacokinetics parameter: Cmax,ss (Day 10); Pharmacokinetics parameter: AUC0-τ,ss (Day 1- Day 10); Pharmacokinetics parameter: Tmax,ss (Day 1-Day 10); Pharmacokinetics parameter: MRT0-τ,ss (Day 1-Day 10): The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. (not_applicable)

Result source: NCT06719310

Bictegravir · Biktarvy

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Reliable signal

NCT02607956 · Phase 3 · completed

This was a randomized, double-blind, active-controlled Phase 3 trial in 657 treatment-naive HIV-1 adults, powered for non-inferiority with a 12% margin. The primary endpoint was the FDA snapshot proportion with HIV-1 RNA <50 copies/mL at Week 48, a clinical virologic endpoint. The pre-specified non-inferiority comparison was met: B/F/TAF 89.4% vs DTG+F/TAF 92.9%, difference -3.5 (95.002% CI -7.9 to 1.0), with the confidence interval entirely within the 12% margin; the superiority test was not significant.

Next expected readout: December 2026 · NCT06830668 (registry estimate)

Reported efficacy

Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis). (met)

Result source: NCT03110380

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointACC017Bictegravir
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT0771122392.4% vs 93%vs ABC/DTG/3TCwk 48 · n 314NCT02607930
5 other results
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT077112230.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
CD4 count, change (week 48)—Trial running · NCT07711223278 vs 289vs DTG + F/TAFwk 144 · n 262NCT02607956
6 other results
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380

HIV-1 RNA below 50 copies/mL (week 48)

ACC017
—Trial running · NCT07711223
Bictegravir
92.4% vs 93%vs ABC/DTG/3TCwk 48 · n 314NCT02607930
5 other results
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694

HIV-1 RNA 50 copies/mL or more (week 48)

ACC017
—Trial running · NCT07711223
Bictegravir
0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380

CD4 count, change (week 48)

ACC017
—Trial running · NCT07711223
Bictegravir
278 vs 289vs DTG + F/TAFwk 144 · n 262NCT02607956
6 other results
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

ACC017
The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. NCT06719310 · Phase 1/2 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ACC017: 0 of 4 rows · Bictegravir: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBictegravir
Dropout rate
18.7%a
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
17.1%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
7.4%B/F/TAF
NCT03110380 · Phase 3
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
5%
NCT04530630 · Phase 4 · registry result, not featured evidence
11.9%
NCT05405751 · Phase 4 · registry result, not featured evidence
—
NCT03656783 · Phase 3 · registry result, not featured evidence
4.6%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
20%50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
20%100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
20%5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
1.2%a
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
0%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
1.1%B/F/TAF
NCT03110380 · Phase 3
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
—
NCT04530630 · Phase 4 · registry result, not featured evidence
—
NCT05405751 · Phase 4 · registry result, not featured evidence
—
NCT03656783 · Phase 3 · registry result, not featured evidence
1.5%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
Serious AEs
20%a
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
14%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
7.5%B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF
NCT03110380 · Phase 3
12.7%Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
9.6%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
9.5%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
5%
NCT04530630 · Phase 4 · registry result, not featured evidence
4%
NCT05405751 · Phase 4 · registry result, not featured evidence
0%
NCT03656783 · Phase 3 · registry result, not featured evidence
—BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
6.2%BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
0%50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
diarrhoea 20.6%
headache 17.8%
nasopharyngitis 15.9%
NCT02607956 · Phase 3 · HIV · phase 3
show 12 more results
diarrhoea 17.2%
upper respiratory tract infection 14.6%
headache 14%
NCT02607930 · Phase 3 · HIV · phase 3
syphilis 8.7%
covid-19 7.9%
nasopharyngitis 7.1%
NCT02607930 · Phase 3 · HIV · phase 3
nasopharyngitis 15.5%
upper respiratory tract infection 11.6%
diarrhoea 9.2%
NCT03110380 · Phase 3
upper respiratory tract infection 7.2%
arthralgia 3.2%
bronchitis 3.2%
NCT03110380 · Phase 3
upper respiratory tract infection 8.6%
diarrhoea 6%
fatigue 6%
NCT03110380 · Phase 3 · combination
loose stool/ diarrhea 25%
NCT04530630 · Phase 4 · registry result, not featured evidence
shortness of breath 8%
NCT03656783 · Phase 3 · registry result, not featured evidence
diarrhoea 13.8%
upper respiratory tract infection 10.8%
headache 9.2%
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
50 mg
fatigue 25% (placebo 0%)
papule 25% (placebo 0%)
arthropod bite 0% (placebo 0%)
NCT02275065 · Phase 1 · registry result, not featured evidence
100 mg
arthropod bite 25% (placebo 0%)
diarrhoea 25% (placebo 0%)
headache 25% (placebo 25%)
NCT02275065 · Phase 1 · registry result, not featured evidence
25 mg
headache 25% (placebo 25%)
arthropod bite 0% (placebo 0%)
blood creatine phosphokinase increased 0% (placebo 0%)
NCT02275065 · Phase 1 · registry result, not featured evidence
5 mg
blood creatine phosphokinase increased 25% (placebo 0%)
diarrhoea 25% (placebo 0%)
headache 25% (placebo 25%)
NCT02275065 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bictegravir

HIV RNA Less Than 50 Copies 89.4% (n=320) vs 92.9% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · HIV · phase 3
show 2 more results
84.1% (n=320) vs 86.5% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · HIV · phase 3
81.9% (n=320) vs 84% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · HIV · phase 3
HIV-1 RNA Less Than 20 82.2% (n=320) vs 87.1% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · HIV · phase 3
show 5 more results
77.5% (n=320) vs 80.3% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · HIV · phase 3
77.5% (n=320) vs 79.1% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · HIV · phase 3
87.6% (n=314) vs 87.3% (n=315) ABC/DTG/3TC @ 48wk
NCT02607930 · Phase 3 · HIV · phase 3
83.4% (n=314) vs 84.8% (n=315) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
78% (n=314) vs 82.2% (n=315) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
HIV-1 RNA -1.37 vs -0.01 placebo log @ 1.57wk50 mg
absolute change · log
NCT02275065 · Phase 1 · registry result, not featured evidence
show 12 more results
-1.61 vs -0.01 placebo log @ 1.57wk100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
-1.33 vs -0.01 placebo log @ 1.57wk25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
-0.92 vs -0.01 placebo log @ 1.57wk5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
-3.07 vs -3.12 DTG + F/TAF log @ 48wk
NCT02607956 · Phase 3 · HIV · phase 3
-3.08 vs -3.1 DTG + F/TAF log @ 96wk
NCT02607956 · Phase 3 · HIV · phase 3
-3.06 vs -3.11 DTG + F/TAF log @ 144wk
NCT02607956 · Phase 3 · HIV · phase 3
-3.11 vs -3.07 ABC/DTG/3TC log @ 48wk
NCT02607930 · Phase 3 · HIV · phase 3
-3.09 vs -3.1 ABC/DTG/3TC log @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
-3.11 vs -3.1 ABC/DTG/3TC log @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
-3.03 vs -3.15 DTG + F/TAF log @ 12wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.09 vs -3.12 DTG + F/TAF log @ 24wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.09 vs -3.11 DTG + F/TAF log @ 48wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
CD4+ 180 vs 201 DTG + F/TAF cells/uL @ 48wk
absolute change · cells/uL
NCT02607956 · Phase 3 · HIV · phase 3
show 6 more results
237 vs 281 DTG + F/TAF cells/uL @ 96wk
NCT02607956 · Phase 3 · HIV · phase 3
278 vs 289 DTG + F/TAF cells/uL @ 144wk
NCT02607956 · Phase 3 · HIV · phase 3
235 vs 228 ABC/DTG/3TC cells/uL @ 48wk
NCT02607930 · Phase 3 · HIV · phase 3
287 vs 288 ABC/DTG/3TC cells/uL @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
299 vs 317 ABC/DTG/3TC cells/uL @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
18 vs 36 DTG + F/TAF cells/uL @ 48wk
NCT03110380 · Phase 3
HIV-1 RNA Less Than 50 Copies 25% (n=4) vs 0% (n=4) placebo @ 2.43wk50 mg
responder rate · % of participants
NCT02275065 · Phase 1 · registry result, not featured evidence
show 10 more results
50% (n=4) vs 0% (n=4) placebo @ 2.43wk100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0% (n=4) vs 0% (n=4) placebo @ 2.43wk25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0% (n=3) vs 0% (n=4) placebo @ 2.43wk5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
92.4% (n=314) vs 93% (n=315) ABC/DTG/3TC @ 48wk
NCT02607930 · Phase 3 · HIV · phase 3
87.9% (n=314) vs 89.8% (n=315) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
81.5% (n=314) vs 84.1% (n=315) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
93.3% (n=284) vs 91.1% (n=281) DTG + F/TAF @ 48wk
NCT03110380 · Phase 3
96.9% (n=65) vs 93.9% (n=33) DTG + F/TAF @ 24wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
93.8% (n=65) vs 93.9% (n=33) DTG + F/TAF @ 12wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
96.9% (n=65) vs 90.9% (n=33) DTG + F/TAF @ 48wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
Hip BMD -0.802% (n=278) vs -1.148% (n=281) ABC/DTG/3TC @ 48wk
percent change · % of baseline
NCT02607930 · Phase 3 · HIV · phase 3
show 2 more results
-1.128% (n=250) vs -1.262% (n=257) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
-1.02% (n=236) vs -1.291% (n=240) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
Spine BMD -0.772% (n=284) vs -0.552% (n=285) ABC/DTG/3TC @ 48wk
percent change · % of baseline
NCT02607930 · Phase 3 · HIV · phase 3
show 2 more results
-0.705% (n=256) vs -0.219% (n=258) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
-0.371% (n=243) vs 0.035% (n=244) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
HIV-1 RNA Ge50 Copies 0.4% (n=284) vs 1.1% (n=281) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT03110380 · Phase 3
Virologic Suppression 100% (n=19) @ 48wk
event count · % of participants
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence · converted to % from 19 Participants as posted
CD4+ 305.8333 cells/uL @ 4wk
absolute change · cells/uL
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence
show 4 more results
342.2105 cells/uL @ 12wk
NCT04530630 · Phase 4 · registry result, not featured evidence
374.8947 cells/uL @ 24wk
NCT04530630 · Phase 4 · registry result, not featured evidence
404.6667 cells/uL @ 36wk
NCT04530630 · Phase 4 · registry result, not featured evidence
382.4211 cells/uL @ 48wk
NCT04530630 · Phase 4 · registry result, not featured evidence
CD4 25.667% (n=19) @ 4wk
percent change · % of baseline
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence
show 4 more results
25.7368% (n=19) @ 12wk
NCT04530630 · Phase 4 · registry result, not featured evidence
27.0526% (n=19) @ 24wk
NCT04530630 · Phase 4 · registry result, not featured evidence
28.1111% (n=19) @ 36wk
NCT04530630 · Phase 4 · registry result, not featured evidence
26.1579% (n=19) @ 48wk
NCT04530630 · Phase 4 · registry result, not featured evidence
Allograft Rejection 0% (n=19) @ 48wk
event count · % of participants
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACC017's landscape · Bictegravir's landscape